AXL
Top inhibitors
| Drug | Inhibition % | Gini |
|---|---|---|
| Gilteritinib | 98.7 | 0.51 |
| Crizotinib | 97.1 | 0.58 |
| Neratinib | 96.3 | 0.60 |
| Cabozantinib | 95.9 | 0.75 |
| Sunitinib | 90.6 | 0.52 |
| Bosutinib | 89.9 | 0.55 |
| Pacritinib | 89.8 | 0.45 |
| Brigatinib | 85.3 | 0.51 |
| Selpercatinib | 85.2 | 0.64 |
| Lazertinib | 81.1 | 0.67 |
| Nintedanib | 79.5 | 0.61 |
| Repotrectinib | 77.8 | 0.61 |
| Pralsetinib | 76.7 | 0.64 |
| Fedratinib | 76.3 | 0.58 |
| Alectinib | 75.8 | 0.65 |
Known variants
Cancer associations
| Mutation | Cancer type | Organ | Source |
|---|---|---|---|
R499C | carcinoma_skin | Skin | https://doi.org/10.1093/nar/gkaa945 |
R499C | carcinoma_large_intestine | Large Intestine | https://doi.org/10.1093/nar/gkaa945 |